echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Roche invests $290 million in Freenome colorectal cancer screening program

    Roche invests $290 million in Freenome colorectal cancer screening program

    • Last Update: 2022-01-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Roche announced an investment of $290 million to support the development of Freenome colorectal cancer detection technology


    Freenome's test is being evaluated in the PREEMPTCRC trial, which is expected to enroll approximately 25,000 patients and is expected to be the largest registry of screening trials for CRC in asymptomatic, average-risk adults in the United States.


    Freenome is an innovative CRC screening test that attempts to detect early-stage colorectal cancer using routine blood draws


    Colorectal cancer is the third most common cancer in the world


    For Roche, the big investment in Freenome will also strengthen the company's diagnostics capabilities


    Freenome expects to initiate additional clinical studies in multiple cancer indications in February of this year


    Freenome has raised more than $1.


    Original English text: https:// href="https://" target="_blank" _href="https://" textvalue="https://">https://

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.